Nutex Health, Inc. Q1 FY2025 earnings call

Management Statement and Operational Highlights

• Patient Visits and Growth: Total patient visits in Q1 2025 were 48,269, a 20.5% increase from Q1 2024. Mature hospitals saw a 5.3% increase in visits, demonstrating sustained demand.
• Financial Results: Total revenue for Q1 2025 was $11.8 million, a 214% increase from Q1 2024. Adjusted EBITDA was $72.8 million, up from a negative $400,000 in Q1 2024. Net income was $14.6 million. Balance sheet was stable with cash at $87.7 million, up from $43.5 million at year-end 2024.
• Arbitration Process: Submitted 60%-70% of billable visits through arbitration in Q1 2025, achieving an 80%+ win rate, leading to facility collections increasing 200%-300% vs initial insurance payments. The arbitration process is being refined with more arbitrators added.
• Micro Hospital Model: Plans to open 3 additional hospitals in 2025, with a pipeline extending to 2028 and 10+ projects in development.
• Cost Management: Facility level operating costs were 44.1% of total revenue in Q1 2025, excluding arbitration costs, operating costs were stable. Labor costs were 16.4% of net revenue, and supply costs decreased 28% from Q1 2024.

Segment Performance

• Hospitals Division: Total revenue for Q1 2025 was $211.8 million, a 214% increase from $67.5 million in Q1 2024. The hospitals revision drove most growth, with mature hospitals (operational before Dec 31, 2022) seeing an 186.5% revenue increase. Total patient visits reached 48,269, a 20.5% increase from Q1 2024, with mature hospitals growing by 5.3%.
• Population Health Division: Revenue increased by ~$400,000 or 5.4% to $7.8 million in Q1 2025 from $7.4 million in Q1 2024, with over 40,000 patients enrolled in IPAs.

Guidance

• Hospital Expansion: Plans to open 3 additional micro hospitals in 2025.
• Arbitration Trend: Trending towards a steady state with better data on reimbursement rates, with 9 months of arbitration payment data available by end of Q2 2025.
• Capital Deployment: Considering options like share buybacks, dividends, and investments in development pipeline, IPAs, and potential M&A activities.

Risks

• Arbitration Process: Low participation due to high costs and long payment times; no significant behavioral changes from insurance companies. Only ~5% of eligible charts are arbitrated due to high costs and extended payment times.
• Legislative/Regulatory: Uncertainties around legislative developments like the Murphy bill and its impact on arbitration timeliness and revenue.

Question and Answer

Q: Bill Sutherland asked if Q1 arbitration metrics are repeatable.

A: Jon Bates discussed trending and data accumulation, noting 9 months of payment data available and trending towards steady state.

Q: Thomas McGovern inquired about new arbitrators and impact on arbitration process.

A: Jon Bates stated more arbitrators would help, as additional arbitrators can alleviate backlog and improve the process.

Q: Gene Mannheimer asked about flu season impact on mature hospital visits.

A: Tom Vo and Josh DeTillio discussed flu season length and community awareness, noting 5% growth in mature hospitals despite flu season differences.

Q: Joshua Cohen asked about capital return options and AR pacing.

A: Jon Bates and Tom Vo talked about capital return options (share buyback, dividends) and AR collection, noting average collection time of ~120 days including arbitration periods.